These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 23484395)

  • 1. [Evaluation of antibody response to HPV vaccination in HIV infected girls].
    Ołdakowska A; Marczyńska M; Dobosz S; Stańska-Perka A; Popielska J; Szczepańska-Putz M
    Przegl Epidemiol; 2012; 66(4):651-5. PubMed ID: 23484395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study.
    Denny L; Hendricks B; Gordon C; Thomas F; Hezareh M; Dobbelaere K; Durand C; Hervé C; Descamps D
    Vaccine; 2013 Nov; 31(48):5745-53. PubMed ID: 24091311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measles antibody in vaccinated human immunodeficiency virus type 1-infected children.
    Arpadi SM; Markowitz LE; Baughman AL; Shah K; Adam H; Wiznia A; Lambert G; Dobroszycki J; Heath JL; Bellini WJ
    Pediatrics; 1996 May; 97(5):653-7. PubMed ID: 8628602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
    Olsson SE; Villa LL; Costa RL; Petta CA; Andrade RP; Malm C; Iversen OE; Høye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; von Krogh G; Lehtinen M; Paavonen J; Tamms GM; Giacoletti K; Lupinacci L; Esser MT; Vuocolo SC; Saah AJ; Barr E
    Vaccine; 2007 Jun; 25(26):4931-9. PubMed ID: 17499406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody responses to prophylactic quadrivalent human papillomavirus vaccine at 48 months among HIV-infected girls and boys ages 9-14 in Kenya, Africa.
    Mugo N; Eckert LO; Odero L; Gakuo S; Ngure K; Celum C; Baeten JM; Barnabas RV; Wald A
    Vaccine; 2021 Jul; 39(33):4751-4758. PubMed ID: 33485644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine coadministered with combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine to girls and young women.
    Garcia-Sicilia J; Schwarz TF; Carmona A; Peters K; Malkin JE; Tran PM; Behre U; Iturbe EB; Catteau G; Thomas F; Dobbelaere K; Descamps D; Dubin G;
    J Adolesc Health; 2010 Feb; 46(2):142-51. PubMed ID: 20113920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.
    David MP; Van Herck K; Hardt K; Tibaldi F; Dubin G; Descamps D; Van Damme P
    Gynecol Oncol; 2009 Dec; 115(3 Suppl):S1-6. PubMed ID: 19217149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 Years of age vaccinated using alternative dosing schedules: results 29 to 32 months after third dose.
    Lamontagne DS; Thiem VD; Huong VM; Tang Y; Neuzil KM
    J Infect Dis; 2013 Oct; 208(8):1325-34. PubMed ID: 23901077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine.
    Giuliano AR; Lazcano-Ponce E; Villa L; Nolan T; Marchant C; Radley D; Golm G; McCarroll K; Yu J; Esser MT; Vuocolo SC; Barr E
    J Infect Dis; 2007 Oct; 196(8):1153-62. PubMed ID: 17955433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High prevalence of high risk human papillomavirus-capsid antibodies in human immunodeficiency virus-seropositive men: a serological study.
    Höpfl R; Petter A; Thaler P; Sarcletti M; Widschwendter A; Zangerle R
    BMC Infect Dis; 2003 Apr; 3():6. PubMed ID: 12723991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The human papillomavirus vaccines.
    Ljubojević S
    Acta Dermatovenerol Croat; 2006; 14(3):208. PubMed ID: 17010274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hepatitis B vaccination effectiveness based on anti-HBs antibodies presence in children vertically infected with HIV].
    Ołdakowska A; Marczyńska M
    Przegl Epidemiol; 2010; 64(2):323-8. PubMed ID: 20731246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of prophylactic human papillomavirus vaccines: recommendations and monitoring in the US.
    Dunne EF; Datta SD; E Markowitz L
    Cancer; 2008 Nov; 113(10 Suppl):2995-3003. PubMed ID: 18980283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protecting our patients from HPV and HPV-related diseases: the role of vaccines.
    Mahoney MC
    J Fam Pract; 2006 Nov; Suppl():10-7. PubMed ID: 17366753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix.
    Schwarz TF
    Adv Ther; 2009 Nov; 26(11):983-98. PubMed ID: 20024678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls.
    Medina DM; Valencia A; de Velasquez A; Huang LM; Prymula R; García-Sicilia J; Rombo L; David MP; Descamps D; Hardt K; Dubin G;
    J Adolesc Health; 2010 May; 46(5):414-21. PubMed ID: 20413076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence.
    Bogaards JA; Coupé VM; Xiridou M; Meijer CJ; Wallinga J; Berkhof J
    Epidemiology; 2011 Jul; 22(4):505-15. PubMed ID: 21540743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women.
    Bhatla N; Suri V; Basu P; Shastri S; Datta SK; Bi D; Descamps DJ; Bock HL;
    J Obstet Gynaecol Res; 2010 Feb; 36(1):123-32. PubMed ID: 20178538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, duration of immunity and cross protection after HPV vaccination: a review of the evidence.
    Bonanni P; Boccalini S; Bechini A
    Vaccine; 2009 May; 27 Suppl 1():A46-53. PubMed ID: 19480962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening.
    Arbyn M; Dillner J
    J Clin Virol; 2007 Mar; 38(3):189-97. PubMed ID: 17258503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.